about
Genetics of type III Bartter syndrome in Spain, proposed diagnostic algorithmLong-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome.Very low-molecular-mass fragments of albumin in the plasma of patients with focal segmental glomerulosclerosis.Targeted next-generation sequencing in steroid-resistant nephrotic syndrome: mutations in multiple glomerular genes may influence disease severityPoor phenotype-genotype association in a large series of patients with Type III Bartter syndrome.Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency.Dent's disease: Identification of seven new pathogenic mutations in the CLCN5 geneIntracranial Hypertension in Cystinosis Is a Challenge: Experience in a Children's Hospital.Delayed graft function is reduced with antithymocyte globulin induction in pediatric kidney transplantation.Mesangial C4d Deposits in Early IgA Nephropathy.Improvement of refractory pruritus after lipoprotein-apheresis in arthrogryposis-renal failure-cholestasis syndrome.Primary distal renal tubular acidosis: novel findings in patients studied by next-generation sequencing.Primary distal renal tubular acidosis: novel findings in patients studied by next-generation sequencing.Novel mutations associated with nephrogenic diabetes insipidus. A clinical-genetic study.TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis.Vascular thrombosis in pediatric kidney transplantation: Graft survival is possible with adequate management.Nephrin mutations cause childhood- and adult-onset focal segmental glomerulosclerosisA kidney-disease gene panel allows a comprehensive genetic diagnosis of cystic and glomerular inherited kidney diseasesReversal of hyperoxaluric cardiomyopathy with severe cardiac dysfunction after combined liver and kidney transplantationCorrection: Claudin-19 Mutations and Clinical Phenotype in Spanish Patients with Familial Hypomagnesemia with Hypercalciuria and NephrocalcinosisSingle-cycle rituximab-induced immunologic changes in children: Enhanced in neuroimmunologic disease?
P50
Q28533619-24F59F10-B221-4512-B1A8-D245FB0F9F9BQ33402795-1594EB21-3645-49A1-8409-3DA6D2EC641EQ33506818-32914BD6-E3EA-41B0-A917-C31C4E1D65E1Q35959709-35C65C07-3684-406D-A220-EE9199DDA94CQ36306188-6899CC0E-54F4-48FB-A5BC-84C07404D0BEQ37672116-2A45E2CD-6FD1-41C6-AFE6-AF90DCF96D4AQ39392915-8AA7930E-A209-4B13-8C8B-9479B42F23F7Q41619269-D1A2B6B4-E81D-43EE-8B78-ACC2A1DE0390Q43283991-AC55899A-ECE9-41DE-81F5-A460EAE170E1Q47394164-2D5C0E80-B13F-4E2B-8147-8466015659D8Q48136011-D2E8D9D3-5391-41A2-A4D7-64345F182B15Q50045856-4A792AF7-BEFB-46D0-97A5-AB66BA79E5F4Q50277888-2407364B-E082-4EF2-B3D3-3E7D484F46C2Q50447371-20764575-C39C-4C0D-B677-F14AAE7A405BQ51637426-7B5BDD04-AB23-4A1F-9281-CF4080633D46Q52627007-398BA1BB-324A-4766-B902-26DBA02FA10BQ63434594-5869CA4A-6AF4-4EE6-B285-FF57ED0652CAQ64045334-C3512BFD-CCE5-4692-8C3D-FCE5429C30DBQ87771947-21A8F122-DB6C-4E31-A09B-8A063E295F76Q93592313-1AA3DC13-DD5C-4583-BB7A-7551EA063C6AQ94590371-3AAEF754-2151-4B77-957C-DEBB55A146E0
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-5942-8488
@en
name
Alvaro Madrid
@ast
Alvaro Madrid
@en
Alvaro Madrid
@es
Alvaro Madrid
@nl
type
label
Alvaro Madrid
@ast
Alvaro Madrid
@en
Alvaro Madrid
@es
Alvaro Madrid
@nl
prefLabel
Alvaro Madrid
@ast
Alvaro Madrid
@en
Alvaro Madrid
@es
Alvaro Madrid
@nl
P106
P21
P31
P496
0000-0002-5942-8488